BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hartounian, Ph.D., Chief Operating Officer, Bob Dagher, M.D., Chief Medical Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.
Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. Eastern Time on Friday, May 16, 2025.
Investors may access the conference call by dialing the following numbers:
Participant Numbers:
Toll Free
888-506-0062
International
973-528-0011
Participant Access Code
621608
Webcast
https://www.webcaster4.com/Webcast/Page/2354/52457
The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.
Replay Numbers:
Toll Free
877-481-4010
International
919-882-2331
Reply Passcode
52457
About Brainstorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a confirmatory Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine.To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), ADCOM meeting related to NurOwn, the timing of a PDUFA action date for the BLA for NurOwn, the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTSInvestors:Michael WoodPhone: +1 646-597-6983mwood@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-reschedules-first-quarter-2025-financial-results-release-to-post-market-close-today-and-sets-investor-call-for-monday-may-19-302456403.html
SOURCE BrainStorm Cell Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Why Rigetti Computing Stock Is Sinking Today
Key Points Q2 revenue was $1.8 million, down roughly 42% year over year; net loss neared $40 million. Soft jobs data and hotter-than-expected inflation data weighed on risk assets like quantum stocks. 10 stocks we like better than Rigetti Computing › Shares of Rigetti Computing (NASDAQ: RGTI) are sinking on Tuesday, down 8.7% as of 2:46 p.m. ET. The drop comes as the S&P 500 loses 0.7% and the Nasdaq Composite loses 1.5%. The quantum computing company's stock is continuing its slide after its recent earnings failed to impress investors and as macro concerns about the direction of the economy are leading investors to jump out of risky stocks. Rigetti Computing stock drops on weak Q2 and macro jitters Last week, Rigetti released its Q2 report, revealing that its sales and earnings were down significantly year over year. The company's $1.8 million in revenue was nearly 42% less than last year in the same period, and its net income dropped nearly 220% as the company lost nearly $40 million in the quarter. While the loss was exacerbated by some one-off accounting charges, the performance still showed how far the company is from justifying its current market cap of nearly $5 billion. Adding to the pain, recent economic data is putting pressure on riskier stocks like Rigetti. The latest jobs report shows the economy may be slowing, while at the same time, inflation numbers came in higher than expected. Investors should be cautious The company did share some promising operational updates and leaps in its technological development in its earnings release, but I believe we are likely many, many years, if not decades, away from viable quantum computing. Despite this, Rigetti and other quantum computing companies are reaching multibillion-dollar valuations already. I think there is a major disconnect here, and quantum investors may get burned if the economy does really take a dive. Should you buy stock in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,076% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Rigetti Computing Stock Is Sinking Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Walmart shrimp may have been exposed to radioactive material, FDA says
The Food and Drug Administration said on Tuesday that the public should avoid eating certain frozen shrimp sold at Walmart due to concerns that the seafood may have been contaminated with radioactive material. Health officials said in a news release that it is investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products processed by an Indonesian company, PT. Bahari Makmur Sejati of Indonesia, also known as BMS Food. Some of the raw frozen shrimp products processed by an Indonesian company are sold at Walmart stores in thirteen states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. Among the products includes Walmart's "great value brand frozen shrimp," the health agency said. "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA said. "Do not eat or serve this product." Health officials advised people to talk to their healthcare providers if they think they've been exposed to elevated levels of the contaminant. PT. Bahari Makmur Sejati and Walmart did not immediately return requests for comment. Cs-137 is the radioactive form of Cesium, "a soft, flexible, silvery-white metal that becomes liquid near room temperature" used for medical devices and gauges, according to the Environmental Protection Agency. Repeated exposure to low doses of Cs-137 can increase the risk of cancer, "resulting from damage to DNA within living cells of the body," health officials said in their news release. The FDA said that the U.S. Customs & Border Protection alerted the health agency to the detection of Cs-137 in shipping containers in Los Angeles, Houston, Savannah and Miami. It said that all containers and product that tested positive for Cs-137 were denied entry into the country. Health officials also cautioned that it did not detect Cs-137 in any product above the current derived intervention levels for Cs-137, of 1200 Bq/kg. However, the FDA said that "the level detected in the breaded shrimp sample could represent a potential health concern" if it is combined with radiation in the environment or from medical procedures. This article was originally published on Solve the daily Crossword
The Hill
20 minutes ago
- The Hill
FDA warns of potentially radioactive frozen shrimp sold at Walmart
The Food and Drug Administration (FDA) is warning consumers not to eat, sell or serve frozen shrimp sold at Walmart due to potential radioactive contamination. The FDA was alerted by U.S. Customs & Border Protection (CBP) about the detection of Cesium-137, a radioactive isotope, in shipping containers at four U.S. ports: Los Angeles, Houston, Savannah, Ga., and Miami. The FDA collected multiple samples for analysis and the results confirmed the presence of Cs-137 in one sample of breaded shrimp distributed by Indonesia's BMS Foods, the agency said in a news release on Tuesday. 'Containers and product testing positive or alerting for Cs-137 have been denied entry into the country,' the FDA said in the update. 'The agency continues to coordinate with CBP to prevent any contaminated products from reaching consumers and is working with Indonesian seafood regulatory authorities to investigate the root cause of the contamination.' None of the shrimp that has entered the U.S. food supply has tested positive for Cs-137, the FDA said. The FDA suggested that all products from BMS Foods sent after the firm's containers tested positive for Cs-137 should be recalled, despite the products not testing positive for the radioactive isotope. Consumers should not eat or serve the following Great Value shrimp products sold at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Missouri, Misssisipi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027. 'FDA has not detected Cs-137 in any product above the current derived intervention levels for Cs-137 (1200 Bq/kg); however, FDA has concluded that the level detected in the breaded shrimp sample could represent a potential health concern for those exposed to this level of Cs-137 from consumption of the shrimp over an extended period of time combined with radiation that exists in the environment and from other sources such as medical procedures,' the agency said on Tuesday.
